Cargando…

Impact of COVID-19 pandemic on the surgical treatment of gastric cancer

OBJECTIVE: The Coronavirus Disease 2019 (COVID-19) pandemic has been recognized as one of the most serious public health crises. This study aimed to evaluate the short-term impact of the pandemic on the surgical treatment of patients with gastric cancer (GC) in addition to their clinicopathological...

Descripción completa

Detalles Bibliográficos
Autores principales: Arneiro, Amanda Juliani, Ramos, Marcus Fernando Kodama Pertille, Pereira, Marina Alessandra, Dias, André Roncon, Zilberstein, Bruno, Ribeiro, Ulysses, Nahas, Sergio Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Faculdade de Medicina / USP 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595635/
https://www.ncbi.nlm.nih.gov/pubmed/34852144
http://dx.doi.org/10.6061/clinics/2021/e3508
_version_ 1784600219966504960
author Arneiro, Amanda Juliani
Ramos, Marcus Fernando Kodama Pertille
Pereira, Marina Alessandra
Dias, André Roncon
Zilberstein, Bruno
Ribeiro, Ulysses
Nahas, Sergio Carlos
author_facet Arneiro, Amanda Juliani
Ramos, Marcus Fernando Kodama Pertille
Pereira, Marina Alessandra
Dias, André Roncon
Zilberstein, Bruno
Ribeiro, Ulysses
Nahas, Sergio Carlos
author_sort Arneiro, Amanda Juliani
collection PubMed
description OBJECTIVE: The Coronavirus Disease 2019 (COVID-19) pandemic has been recognized as one of the most serious public health crises. This study aimed to evaluate the short-term impact of the pandemic on the surgical treatment of patients with gastric cancer (GC) in addition to their clinicopathological characteristics. We also verified adherence to the COVID-19 screening protocol adopted in the institution. METHODS: All patients with GC who underwent surgical treatment between 2015 and 2021 were retrospectively evaluated and divided into two groups according to the time period: control group (2015-2019) and COVID group (2020-2021). The institutional protocol recommends that patients referred for surgery undergo RT-PCR for severe acute respiratory syndrome coronavirus 2 infection. RESULTS: A total of 83 patients were classified into the COVID group and 535 into the control group. The number of surgical procedures performed in the control group was 107 (SD±23.8) per year. Diagnostic procedures (p=0.005), preoperative chemotherapy (p<0.001), and adenocarcinomas without Lauren's subtype (p=0.009) were more frequent in the COVID group than in the control group. No significant difference was observed in the pathological characteristics and surgical outcomes of curative GC between the two groups. Evaluation of protocol compliance showed that of 83 patients with GC in the COVID group, 19 (22.9%) were not tested for COVID-19 before surgery. Two patients tested positive for COVID-19 (one preoperative and one postoperative). CONCLUSION: A decrease in the average number of surgeries and a higher frequency of diagnostic procedures occurred during the pandemic than in the previous time period. Tumor/node/metastasis classification, morbidity rates, and mortality rates in patients with GC during the pandemic did not differ from those in the previous time period. Accordingly, GC surgical treatment with acceptable screening protocol compliance could be safely performed during the COVID-19 pandemic.
format Online
Article
Text
id pubmed-8595635
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Faculdade de Medicina / USP
record_format MEDLINE/PubMed
spelling pubmed-85956352021-11-19 Impact of COVID-19 pandemic on the surgical treatment of gastric cancer Arneiro, Amanda Juliani Ramos, Marcus Fernando Kodama Pertille Pereira, Marina Alessandra Dias, André Roncon Zilberstein, Bruno Ribeiro, Ulysses Nahas, Sergio Carlos Clinics (Sao Paulo) Original Article OBJECTIVE: The Coronavirus Disease 2019 (COVID-19) pandemic has been recognized as one of the most serious public health crises. This study aimed to evaluate the short-term impact of the pandemic on the surgical treatment of patients with gastric cancer (GC) in addition to their clinicopathological characteristics. We also verified adherence to the COVID-19 screening protocol adopted in the institution. METHODS: All patients with GC who underwent surgical treatment between 2015 and 2021 were retrospectively evaluated and divided into two groups according to the time period: control group (2015-2019) and COVID group (2020-2021). The institutional protocol recommends that patients referred for surgery undergo RT-PCR for severe acute respiratory syndrome coronavirus 2 infection. RESULTS: A total of 83 patients were classified into the COVID group and 535 into the control group. The number of surgical procedures performed in the control group was 107 (SD±23.8) per year. Diagnostic procedures (p=0.005), preoperative chemotherapy (p<0.001), and adenocarcinomas without Lauren's subtype (p=0.009) were more frequent in the COVID group than in the control group. No significant difference was observed in the pathological characteristics and surgical outcomes of curative GC between the two groups. Evaluation of protocol compliance showed that of 83 patients with GC in the COVID group, 19 (22.9%) were not tested for COVID-19 before surgery. Two patients tested positive for COVID-19 (one preoperative and one postoperative). CONCLUSION: A decrease in the average number of surgeries and a higher frequency of diagnostic procedures occurred during the pandemic than in the previous time period. Tumor/node/metastasis classification, morbidity rates, and mortality rates in patients with GC during the pandemic did not differ from those in the previous time period. Accordingly, GC surgical treatment with acceptable screening protocol compliance could be safely performed during the COVID-19 pandemic. Faculdade de Medicina / USP 2021-11-17 2021 /pmc/articles/PMC8595635/ /pubmed/34852144 http://dx.doi.org/10.6061/clinics/2021/e3508 Text en Copyright © 2021 CLINICS https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.
spellingShingle Original Article
Arneiro, Amanda Juliani
Ramos, Marcus Fernando Kodama Pertille
Pereira, Marina Alessandra
Dias, André Roncon
Zilberstein, Bruno
Ribeiro, Ulysses
Nahas, Sergio Carlos
Impact of COVID-19 pandemic on the surgical treatment of gastric cancer
title Impact of COVID-19 pandemic on the surgical treatment of gastric cancer
title_full Impact of COVID-19 pandemic on the surgical treatment of gastric cancer
title_fullStr Impact of COVID-19 pandemic on the surgical treatment of gastric cancer
title_full_unstemmed Impact of COVID-19 pandemic on the surgical treatment of gastric cancer
title_short Impact of COVID-19 pandemic on the surgical treatment of gastric cancer
title_sort impact of covid-19 pandemic on the surgical treatment of gastric cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595635/
https://www.ncbi.nlm.nih.gov/pubmed/34852144
http://dx.doi.org/10.6061/clinics/2021/e3508
work_keys_str_mv AT arneiroamandajuliani impactofcovid19pandemiconthesurgicaltreatmentofgastriccancer
AT ramosmarcusfernandokodamapertille impactofcovid19pandemiconthesurgicaltreatmentofgastriccancer
AT pereiramarinaalessandra impactofcovid19pandemiconthesurgicaltreatmentofgastriccancer
AT diasandreroncon impactofcovid19pandemiconthesurgicaltreatmentofgastriccancer
AT zilbersteinbruno impactofcovid19pandemiconthesurgicaltreatmentofgastriccancer
AT ribeiroulysses impactofcovid19pandemiconthesurgicaltreatmentofgastriccancer
AT nahassergiocarlos impactofcovid19pandemiconthesurgicaltreatmentofgastriccancer